Company / Revenue per Share
Cartesian Therapeutics, Inc. Revenue per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue per Share
$1.51
FY2025
5-year range
$0.06 / $4.82
FY2021-FY2025
Trend
-68.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $0.56 to $1.51 over the past 2 years.
Based on SEC 10-K filings.
1.51 in FY2025 with a 5-year CAGR of +170.3%.
Improved from $0.56 to $1.51 over the past 2 years.
Revenue per Share over time
Growth rates
- 3-Year CAGR
- +124.1%
- 5-Year CAGR
- +170.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, revenue per share decreased 68.7% year-over-year.
- Peak revenue per share was recorded in FY2024.
- Lowest revenue per share in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score -0.06 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Revenue per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.51 | -68.7% |
| FY2024 | $4.82 | +766.6% |
| FY2023 | $0.56 | +314.1% |
| FY2022 | $0.13 | +117.3% |
| FY2021 | $0.06 | +490.6% |
| FY2020 | $0.01 | +13.6% |
| FY2019 | $0.01 | -99.3% |
| FY2016 | $1.40 | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026